Neuro-Oncology Advance Access published online on October 15, 2009
Neuro-Oncology, doi:10.1093/neuonc/nop005
Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines
State Key Laboratory for Cancer Research in Southern China, Department of Neurosurgery/Neuro-Oncology, Cancer Center, Sun Yat-Sen University, Guangzhou, People's Republic of China (J.F., C.-J.S., F.-R.C., Z.-P.C.); Department of Anatomical & Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, People's Republic of China (H.-K.N.)
Corresponding Author: Zhong-Ping Chen, Cancer Center, Sun Yat-Sen University Guangzhou, Guangdong 510060, People's Republic of China (chenzp57{at}mail.sysu.edu.cn).
| Abstract |
|---|
Autophagy represents an alternative tumor-suppressing mechanism that overcomes the dramatic resistance of malignant gliomas to radiotherapy and proapoptotic-related chemotherapy. This study reports that valproic acid (VPA), a widely used anti-epilepsy drug, induces autophagy in glioma cells. Autophagy, crucial for VPA-induced cell death, is independent of apoptosis, even though apoptotic machinery is proficient. Oxidative stress induced by VPA occurs upstream of autophagy. Oxidative stress also activates the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway, whereas blocking this pathway inhibits autophagy and induces apoptosis. VPA-induced autophagy cannot be alleviated by inositol, suggesting a mechanism different from that for lithium. Moreover, VPA potentiates autophagic cell death, but not apoptosis, when combined with other autophagy inducers such as rapamycin, Ly294002, and temozolomide in glioma cells both in vitro and in vivo, which may warrant further investigation toward possible clinical application in patients with malignant gliomas.
Keywords: autophagy, glioma, oxidative stress, valproic acid
Received July 30, 2008; Accepted June 9, 2009